Excessive MYC Orchestrates Macrophages induced Chromatin Remodeling to Sustain Micropapillary‐Patterned Malignancy in Lung Adenocarcinoma
Abstract Current understanding of micropapillary (MP)‐subtype lung adenocarcinoma (LUAD) remains confined to biological activities and genomic landscapes. Unraveling the major regulatory programs underlying MP patterned malignancy offers opportunities to identify more feasible therapeutic targets fo...
Saved in:
| Main Authors: | , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2025-03-01
|
| Series: | Advanced Science |
| Subjects: | |
| Online Access: | https://doi.org/10.1002/advs.202403851 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| Summary: | Abstract Current understanding of micropapillary (MP)‐subtype lung adenocarcinoma (LUAD) remains confined to biological activities and genomic landscapes. Unraveling the major regulatory programs underlying MP patterned malignancy offers opportunities to identify more feasible therapeutic targets for patients with MP LUAD. This study shows that patients with MP subtype LUAD have aberrant activation of the MYC pathway compared to patients with other subtypes. In vitro and xenograft mouse model studies reveal that MP pattern in malignancy cannot be solely due to aberrant MYC expression but requires the involvement of M2‐like macrophages. Excessively expressed MYC leads to the accumulation of M2‐like macrophages from the bone marrow, which secretes TGFβ, to induce the expression of FOSL2 in tumor cells, thereby remodeling chromatin accessibility at promoter regions of MP‐pattern genes to promote the MYC‐mediated de novo transcriptional regulation of these genes. Additionally, the MP‐pattern in malignancy can be effectively alleviated by disrupting the TGFβ‐FOSL2 axis. These findings reveal new functions for the M2‐like macrophage‐TGFβ‐FOSL2 axis in MYC‐overexpressing MP‐subtype LUAD, identifying targetable vulnerabilities in this pathway. |
|---|---|
| ISSN: | 2198-3844 |